Status:
TERMINATED
Zemedy Application for Irritable Bowel Syndrome
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Bold Health Inc.
Conditions:
IBS - Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.
Detailed Description
Irritable bowel syndrome (IBS) is defined as having recurrent abdominal pain associated with defecation or a change of bowel habits. The pathophysiology of IBS can be looked through the biopsychosocia...
Eligibility Criteria
Inclusion
- Male and female patients \>=18 years old.
- Meet Rome IV criteria for IBS for at least 6 months. No restrictions on type of IBS.
- English proficiency (in order to understand use of the application.
- Patient must be on a stable regimen for IBS for at least 30 days.
- Patients must own a smartphone (iOS or Android) in order to participate in the CBT application.
Exclusion
- Laboratory or imaging evidence of an alternative explanation of patient's symptoms.
- Active gastrointestinal disease such as Crohn's disease, ulcerative colitis, history of complete colon resection, acute infection, or any disease that precludes participation in CBT application.
- Patient already undergoing cognitive behavioral therapy.
- Psychiatric hospitalization within 10 years.
- Current or past diagnosis of a major mental illness such as schizophrenia, bipolar disorder, personality disorder or substance abuse.
- Active (within the past 3 months) suicidal ideation.
- Prisoners or other detained individuals.
- Adults unable to consent.
- Pregnant people.
Key Trial Info
Start Date :
October 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2024
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04723056
Start Date
October 15 2021
End Date
March 8 2024
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Redwood City, California, United States, 94063